In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged Angiogenesis, bispecific antibody, diabetic macular edema, DME, Exudation and Degeneration 2022, eye injections, eye medicine, Levi Garraway M.D. Ph.D., Neovascular AMD, ranibizumab, retinal conditions, RHINE, Roche, Susvimo, Susvimo Archway, Vabysmo, vision loss, YOSEMITE
HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA), ein deutscher Anbieter von Sample-to-Insights-Lösungen, die es Kunden ermöglichen, Einblicke in die Bausteine des Lebens – DNA, RNA und Proteine … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON Tuberkulose, QuantiFERON-TB Gold Plus, TB-Bakterien, TB-Diagnose, TB-Infektionen, TB-Tests, TST, Tuberkulin-Hauttest, UNITAID, Weltgesundheitsorganisation, WHO
(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt Prime Standard : QIA), une société allemande fournisseur de solutions Sample to Insights qui permettent aux clients de débloquer des informations sur … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Académie chinoise des sciences médicales, bactérie de la tuberculose, dépistage de la tuberculose, diagnostic de la tuberculose, Dr. Gao Lei, IGR, infections tuberculeuses, Jean-Pascal Viola, NMPA, OMS, Organisation mondiale de la santé, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB® Gold Plus, test cutané à la tuberculine, TST, UNITAID
(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN N.V., QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB Gold Plus, TB bacteria, TB diagnosis, TB infections, TB testing, TST, Tuberculin Skin Test, UNITAID, WHO, World Health Organization
(PRESS RELEASE) MELBOURNE, Australia, 3-Feb-2022 — /EuropaWire/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged AAVs, adeno-associated viral vectors, Arch Ventures, Australian technologist, Biotech, Codiak Biociences, Daisy Scarborough, DNA/RNA, Dr Ian Dixon, Evox Therapeutics, EVPS, Exopharm, Exoria, exosome therapeutics, exosomes, gene therapies, genetic disorders, LEAP™, lipid nanoparticles, LNPs, LOAD, Lonza, medicine, Pharmaceutical, vaccines
Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern AlivaMab Mouse bietet hochmoderne transgene Mausplattformen, die humane therapeutische Antikörper mit hoher Vielfalt liefern Almirall wird mit AlivaMab Discovery Services … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged Ablexis, AlivaMab Discovery Services, AlivaMab Mouse, Almirall, Antikörpermedikament, Antikörpertherapeutika, Biopharmazeutika, dermatologische Erkrankungen, Dr. Thomas Huber, Hautgesundheit, humantherapeutische Antikörper, Justin Mika, Larry Green, Lizenzvereinbarung, schwere Hauterkrankungen
Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Ablexis, AlivaMab Discovery Services, AlivaMab Mouse, Almirall, antibody drug, antibody therapeutics, biopharmaceutical, dermatological conditions, Dr. Thomas Huber, human therapeutic antibodies, Justin Mika, Larry Green, licensing agreement, severe skin diseases, skin health
(COMMUNIQUÉ DE PRESSE) DARMSTADT, 24-Jan-2022 — /EuropaWire/ — Merck (ETR : MRK), une multinationale allemande leader dans le domaine scientifique et société technologique spécialisée dans les soins de santé, les sciences de la vie et l’électronique, a annoncé que la société … Read the full press release
Posted in Germany, Healthcare, News, Non Profit, Pharma & Biotech, Society
(PRESS RELEASE) DARMSTADT, 24-Jan-2022 — /EuropaWire/ — Merck (ETR: MRK), a German multinational leading science and technology company in healthcare, life science, electronics, has announced the company hit a milestone mark in its donation of praziquantel for the treatment of … Read the full press release
Posted in Germany, Healthcare, News, Non Profit, Pharma & Biotech, Society
Tagged central Africa, donation, DRC, medication, Merck, NTDs, parasitic diseases, Peter Guenter, praziquantel, public health, Rwanda, schistosomiasis, Schistosomiasis Elimination Program, schoolchildren, tropical countries, WHO, World Health Organization
Dupixent ist das erste und einzige Medikament mit positiven Phase-3-Ergebnissen bei Prurigo nodularis, was den potenziellen Nutzen einer gezielten Behandlung von IL-4 und IL-13, zentralen Treibern von Typ-2-Entzündungen, zur Behandlung von Juckreiz und Hautläsionen bestätigt Die Daten bestätigen die Ergebnisse … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged anhaltender Juckreiz, asthma, Atemwegserkrankungen, atopische Dermatitis, dermatologische Erkrankungen, dupilumab, Dupixent, entzündliche Hauterkrankung, extremer Juckreiz, George D. Yancopoulos, Hauterkrankungen, Hautläsionen, Knötchen, Naimish Patel, prurigo nodularis, Regeneron, unerträglicher Juckreiz
Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, biotechnologie, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Ernennung, F&E, Forschung und Entwicklung, Genome Research, Genomik, GlaxoSmithKline plc, GSK, Immunologie, Imperial College, Infektionskrankheiten, Jemperli, künstliche Intelligenz, maschinelles Lernen, Medikamente, Nucala, Onkologie, Pfizer, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged asthma, atopic dermatitis, CRSwNP, dermatological diseases, dupilumab, Dupixent, extreme itch, George D. Yancopoulos, inflammatory skin disease, Naimish Patel, nodules, persistent itch, prurigo nodularis, Regeneron, respiratory diseases, skin diseases, skin lesions, unbearable itch
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, appointment, artificial-intelligence, biotechnology, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Genome Research, genomics, GlaxoSmithKline plc, GSK, immunology, Imperial College, infectious disease, Jemperli, Machine Learning, medicines, Nucala®, oncology, Pfizer, R&D, research and development, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Joint press release by WACKER and Biosyntia (PRESS RELEASE) MUNICH/ COPENHAGEN, 11-Jan-2022 — /EuropaWire/ — WACKER Group (ETR: WCH), a German multinational chemical company, has announced it will partner with Biosyntia, a biotech startup within synthetic biology and metabolic engineering … Read the full press release
Posted in Business, Chemicals, Denmark, Germany, News, Pharma & Biotech
Tagged Biosyntia, Biotech, biotin, coenzyme, dietary supplement, EFSA, European Food Safety Authority, fermentation-based biotin, hair, macronutrient metabolisms, Martin Plambech, nervous system, nutraceutical ingredients, skin, Susanne Leonhartsberger, sustainable fermentation, vitamin B7, vitamins, WACKER Group
Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bayer AG, Cas enzymes, Cas14, Casɸ, cell therapy, CRISPR, Dr. Imke Meyer, Dr. Peter Nell, gene augmentation, gene editing, gene therapy, gene-editing technology, gene-editing therapies, iPSC, liver diseases, Mammoth Biosciences, Mohana Ray, pluripotent stem cell, Stefan Oelrich, vivo projects
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days The secondary … Read the full press release
Expanding range of applications for growing base of QIAcuity digital PCR instruments Two new collaborations: Atila BioSystems expands menu to non-invasive prenatal testing (NIPT), while Actome partnership designed to enable for the first time protein analysis using digital PCR technology … Read the full press release
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aclidinium bromide, Adrian Kemp, Almirall S.A., AstraZeneca, biopharmaceutical, Bretaris, Brimica, Chronic obstructive pulmonary disease, Covis Pharma, Covis Pharma Group, dry powder inhaler, Duaklir, Eklira, formoterol, Genuair, inhaled respiratory medicines, LABA, LAMA, muscarinic antagonist, Tudorza
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This … Read the full press release
Posted in Education, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged 6th annual EU Patients as Partners, AbbVie, Biotech, clinical development, clinical research, clinical trial, clinical trials, Conference, Conference Forum, data, dct, decentralized, DNA, EMD Serono, Gilead Sciences, GSK, INNOVATION, Ipsen, Janssen, Johnson & Johnson, Medicines Development, Merck KGaA, Michaela Dinboeck, MS trial, Noema Pharma, Novartis, Parkinsons disease, patient engagement, patient input, Patient Voice, patients, Patients as Partners Europe, Pfizer, pharma, Pharmaceutical, Pierre Fabre, Regeneron, Takeda, UCB
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?